Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

Phase 3CompletedNCT00099801

Novartis Pharmaceuticals

Overview

The safety and efficacy of FTY720 is being evaluated in patients who receive a kidney transplant.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Kidney Transplantation

Interventions

FTY720DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients undergoing their first kidney transplant * Male or female age 18 to 65 years Exclusion Criteria: * Patients in need of second kidney transplant or multi-organ transplants.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.